Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer

Hope Rugo, MD, FASCO and Aditya Bardia MD, MPH, FASCOexplore strategies for managing antibody drug conjugate (ADC)-related toxicities in breast cancer, covering current ADCs, real-world management practices, and future directions, in this OncLive Insights video series.

EP. 1: Overview of Current ADCs in Breast Cancer

August 21st 2024

Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).

EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components

August 21st 2024

Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.

EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

August 28th 2024

This discussion explores the occurrence and risk factors of neutropenia associated with SG treatment, comparing clinical practice experiences with trial data.

EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia

August 28th 2024

This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.

EP. 5: Navigating SG-related Diarrhea

September 4th 2024

Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.

EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea

September 4th 2024

Panelists discuss how to manage side effects of sacituzumab govitecan (SG), including counseling on alopecia, proactive management strategies, routine antiemetic premedications, and adjustments for chemotherapy-induced nausea and vomiting, as well as recommended breakthrough antinausea medications for home use.

EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

September 11th 2024

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd

September 11th 2024

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.

EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

September 18th 2024

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

September 18th 2024

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.